TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02218944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response Inhibition Training
Description: The primary purpose of this research is to examine the feasibility and efficacy of a smoking specific response inhibition training program in the context of a quit attempt. The task is based on a modified stop-signal task. The study utilizes a one-way nested design with three conditions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Response Inhibition Training
Description: The primary purpose of this research is to examine the feasibility and efficacy of a smoking specific response inhibition training program in the context of a quit attempt. The task is based on a modified stop-signal task. The study utilizes a one-way nested design with three conditions.
Study: NCT03110575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: 2 x TNX-102 SL, 2.8mg tablets taken daily at bedtime for 12 weeks
Study: NCT03779074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10d bismuth quadruple therapy
Description: rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14d hybrid therapy
Description: a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14D high-dose dual therapy
Description: rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days
Study: NCT05382611

Intervention type: DIAGNOSTIC_TEST
Intervention: ngs next generation sequencing
Description: the samples from aneurysmatic tissue and healthy aortic tissue will be investigated using NGS

Intervention type: DIAGNOSTIC_TEST
Intervention: ngs next generation sequencing
Description: the samples from aneurysmatic tissue and healthy aortic tissue will be investigated using NGS
Study: NCT01391988

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electric scalpel
Description: Radical mastectomy with electric scalpel. Electric scalpels were calibrated at 40 watts of cutting and coagulation power.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Description: Radical mastectomy with harmonic scalpel. Harmonic GEN04 generator calibrated at power leve 3 and 5, using the HP054 handpiece and HF 105 curved blade
Study: NCT00696514

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12, folic acid, Vitamin D3
Description: 500 µg vitamin B12; 0.4 mg folic acid; 600 IU vitamin D3 in one capsule, once per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vitamin D3) - 600 IU per day
Description: 600 IU vitamin D3 in one capsule, once per day
Study: NCT04171973

Intervention type: DEVICE
Group type: OTHER
Intervention: Driving an electric wheelchair in real condition
Description: For the control group, 3 test circuits of pipes in real condition of increasing difficulty are tested. Patients perform 2 passes in this condition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Driving an electric wheelchair in virtual condition
Description: For the virtual reality group, the circuits have been digitized. Patients perform 2 passes in this condition.
Study: NCT00174915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 80 mg, orally, once daily for up to 28 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 120 mg, orally, once daily for up to 28 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 240 mg, orally, once daily for up to 28 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol, orally, once daily for up to 28 weeks. Dose of allopurinol received was based on renal status. Subjects with serum creatinine ≤1.5 mg/dL received 300 mg once daily; subjects with serum creatinine \>1.5 mg/dL and ≤2.0 mg/dL received 100 mg once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, orally, once daily for up to 28 weeks.
Study: NCT02820896

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive single or multiple doses of RO7105705 matching placebo IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive single or multiple doses of RO7105705 matching placebo IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7105705
Description: Participants will receive single or multiple doses of RO7105705 IV or SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7105705
Description: Participants will receive single or multiple doses of RO7105705 IV or SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7105705
Description: Participants will receive single or multiple doses of RO7105705 IV or SC.
Study: NCT01127308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin 25 mg will be administered as a single oral suspension containing approximately 100 uCi of \[14C\]ertugliflozin
Study: NCT03993197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological and corporal group management
Description: After inclusion, patient will be divided into groups of 6 or 8 patients either in pre-operative or post-operative phase. Patient care will take place entirely in pre-operative or post-operative phase.~Each group will benefit of six one hour and a half sessions.~The frequency is established as follows:~* First week a session of Body Strategy ©~* Second week a psychological session with group of speech (Photolanguage ©).~* Third week is a break Then the cycle currently described is repeated, for a total of 6 alternate sessions
Study: NCT03161431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and C-X-C Motif Chemokine Receptor 2 (CXCR2)
Study: NCT00982202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: 15mg tablet daily, increase by one pill at one-week intervals based on reported tolerability; maintain best tolerated dose (1 to 3 tablets daily) for \~18months
Study: NCT02291549

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Mometasone furoate nasal spray
Description: Mometasone furoate nasal spray (200mcg) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Description: Mometasone furoate nasal spray (200mcg) once daily
Study: NCT00982202

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 to 3 tablets daily for \~18 months
Study: NCT03355677

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Case finding Clinic
Description: Case finding clinic - participants will be reviewed by a respiratory specialist team. Full respiratory history will be taken and physical examination will be preformed. The participant will then complete 3 quality of life and functionality questionnaires the MRC dyspnoea score and the COPD diagnostic questionnaire. They will then be asked to perform FeNO CO and spirometry measurements.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: At Risk Case Clinics
Description: Complex Case Clinic participants will be reviewed by a respiratory specialist team. Full respiratory history will be taken and physical examination will be preformed. The participant will then complete 6 quality of life and functionality questionnaires . They will then be asked to perform FeNO CO and spirometry measurements. Participants inhaler technique will be checked and any errors corrected. Smoking cessation advice and support will be given if necessary. Each participant will be given an individualised self management plan.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: The control surgeries selected by the HHRA will continue with usual care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: The control surgeries selected by the HHRA will continue with usual care.
Study: NCT01014039

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible Sigmoidoscopy Screening arm
Description: sigmoidoscopy screening
Study: NCT03267914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tray
Description: Control intervention Patients will use the custom-made tray to apply the fluoride locally to the teeth and wear for 5 minutes each day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brush
Description: Patients will brush with the fluoride for 2 minutes each day.
Study: NCT02357589

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2D laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D laparoscopic cholecystectomy
Study: NCT02657902

Intervention type: PROCEDURE
Intervention: Fractures were treated with a Gamma 3 intramedullary nail

Intervention type: PROCEDURE
Intervention: Fractures were treated with a Gamma 3 intramedullary nail + U-Blade
Study: NCT02291549

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: In-office bilateral sham procedure, consisting of advancement of a delivery system with the S8 Sinus Implant into the ethmoid sinuses followed by removal without deployment.
Study: NCT00272415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-1001
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Oral repeating dose
Study: NCT01127529

Intervention type: BIOLOGICAL
Intervention: Protein C Concentrate (Human)
Description: Commercially available Ceprotin will be prescribed, obtained and administered by the investigator according to local standard of care.
Study: NCT02804581

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gum Arabic
Description: Oral intake of GA in powder from30 grams per day
Study: NCT05994105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art based Augmented Reality
Description: The participants will be provided 14 sessions management plan
Study: NCT02143427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: Behavioral: computer-based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 6 sessions with relatives of the child in most cases with the parents.~Arms: Social Skills Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Program with techniques to activate resources
Description: Behavioral: Treatment Program with techniques to activate resources 16 sessions with the child aiming at the reduction of peer related aggressive behavior via activate resources. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent computer based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training.~Arms: Treatment Program with techniques to activate resources of the child and subsequent Social Skills Training
Study: NCT05099458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Additional blood sampling (100 ml)
Description: only an additional blood volume will be collected at the same time of the standard blood collection for these patients
Study: NCT00980850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baxter Novel Influenza A H1N1 Whole Virus Vaccine
Description: Two 0.5 ml doses of vaccine given within 3 weeks interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine
Description: Two 0.25 ml doses of vaccine given within 3 weeks interval
Study: NCT04490902

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limbal transplantation combined with central penetrating keratoplasty
Description: Limbal transplantation combined with central penetrating keratoplasty with single donor cornea

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limbal transplantation combined with central penetrating keratoplasty
Description: Limbal transplantation combined with central penetrating keratoplasty with mixed component cornea
Study: NCT02843113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4 Your Child Program
Description: Integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4 Your Child Program
Description: Integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.
Study: NCT02700932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoWay
Description: solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wave length of 785±20 nm that was added to the system
Study: NCT00149227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan add-on arm: valsartan 40-160 mg per day, and an additional antihypertensive drugs other than ARB and ACEI are administered if necessary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-ARB
Description: 'Non-ARB' was defined conventional anti-hypertensive treatment except for ACEIs and ARBs
Study: NCT02691078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide
Description: The patient will undercome an PET/CT exam with 99m Tc - HYNIC -TOC EDDA, after 20 days of wash out, the same patient will undercome the same exam with 111In - DTPA-octreotide in order to compare both radiopharmaceuticals
Study: NCT01790633

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ELISA
Description: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Test
Description: A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.
Study: NCT00384969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 and Sorafenib
Description: RAD001 2.5mg to 10.0mg PO QD Sorafenib 400mg PO BID
Study: NCT03814876

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group session psycho-education
Description: Active comparator - control group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group session psycho-education
Description: Active comparator - control group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FITS
Description: Manualized family intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FITS
Description: Manualized family intervention
Study: NCT03377985

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: brachial plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: brachial plexus block
Study: NCT02929875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education based on TPB
Description: Three Training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions.
Study: NCT04313660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib In Combination With PD-1/L1 Inhibitor
Description: At the end of chest radiotherapy (c2d1), the simultaneous administration of androtinib hydrochloride capsule and PD-1 / L1 inhibitor was started. L~Arotinib hydrochloride capsule, 12 mg, Po, QD, was taken orally for two weeks, one week, three weeks as a cycle, completed in the first 14 days until the disease progress;~Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.~Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.~The choice of durvalumab / trepril mAb was at the discretion of the researchers.
Study: NCT01749228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac Capsules USP 300 mg
Description: 300 mg capsule once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etodolac
Description: 500 mg tablet once a day
Study: NCT04768439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Vitamin D
Description: Patients will receive a 200 IU/d vitamin D since they tolerate full enteral nutrition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Vitamin D
Description: Patients will receive 1600 IU/d vitamin D since they tolerate full enteral nutrition.
Study: NCT02155725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Fibrinogen concentrate
Description: Injection as soon as possible and within 30 min following the start of prostaglandin infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As soon as possible and within 30 min following the start of prostaglandin infusion
Study: NCT01442961

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopy, laparoscopic hysterectomy
Description: laparoscopic hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vaginal : vaginal hysterectomy
Description: Vaginal hysterectomy
Study: NCT03029494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stabilization splint
Description: Hard acrylic type of splint with full coverage of occlusal surfaces of upper teeth, with a thickness of about 1.5 mm at the level of the first molar.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: sugar pill manufactured to mimic 1000 mg Vitamin C

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: placebo splint
Description: Ineffectively designed oral appliance: an acrylic palatal plate will be used (without influence on occlusion, TMJ and masticatory muscles).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: 1000 mg
Study: NCT02798809

Intervention type: OTHER
Intervention: Clinical dental examination
Description: Clinical dental examination and a questionnaire that was filled out by the parents before each clinical examination.
Study: NCT01621659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team intervention
Description: Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
Study: NCT04264611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Short Foot Exercise Group
Description: Short foot exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Towel Curl Exercise Group
Description: Towel curl exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
Study: NCT00514241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The GPS™ II Platelet Concentrate Separation Kit
Description: The GPS™ II Platelet Concentrate Separation Kit system is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of blood at the patient's point of care. The PRP can be mixed with autograft and allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements.
Study: NCT00733096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Two transforaminal epidural injections of 4 mg, two weeks apart
Study: NCT01699711

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epigallocatechin-3-gallate (EGCG)
Description: EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Epigallocatechin-3-gallate (EGCG)
Description: EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
Study: NCT03161431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and C-X-C Motif Chemokine Receptor 2 (CXCR2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized antibody that targets the programmed cell death 1 receptor (PD-1).
Study: NCT00438594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home visitation
Description: Home visits from mid-pregnancy until child age 2. Group 2 is visits by a paraprofessional; group 3 is visits by nurses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home visitation
Description: Home visits from mid-pregnancy until child age 2. Group 2 is visits by a paraprofessional; group 3 is visits by nurses.
Study: NCT01501123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: 5mg IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: IM midazolam
Study: NCT02255500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine FNB
Description: A single administration of bupivacaine HCl 0.5% with epinephrine 1:200,000 in 20 mL volume will be administered within 2 hours prior to the surgical procedure as an ultrasound-guided FNB.